BLCM News and Press, Bellicum Pharmaceuticals Inc. From 01/26/22

HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the B. Riley Securities 2022 Virtual Oncology Con...

Listing Qualifications Hearings Department of The Nasdaq informed Bellicum Pharmaceuticals (NASDAQ:BLCM) that it has regained compliance with Listing Rule wherein it requires stockholders’ equity of at least $2.5M for continued listing of the company’s common stock. The not...

HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Ma...

Alset EHome International (NASDAQ:AEI) -43% prices $30M stock offering TuanChe (NASDAQ:TC) -18%. Lucid Group (NASDAQ:LCID) -15%. Hut 8 Mining (NASDAQ:HUT) -15%. Bitfarms (NASDAQ:BITF) -15%. Aeglea BioTherapeutics (NASDAQ:AGLE) -14% says pivotal trial for pegzilarginase in ...

Bellicum Pharmaceuticals (NASDAQ:BLCM) announces positive interim data from its Phase 1/2 GoCAR-T clinical trials, in the first cohort of metastatic castration-resistant prostate cancer (mCRPC) patients treated in the clinical trial for BPX-601. Shares down 8.3% premarket at $1.55. ...

- Confirmed partial response observed in one patient in first cohort of metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 - - Favorable safety profile observed in initial dose cohort of BPX-603 in HER2+ solid tumors - - Financing expec...

- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief Development Officer effective December 1, 2021 - HOUSTON, Nov. 04, 20...

The following slide deck was published by Bellicum Pharmaceuticals, Inc. in conjunction with this event. For further details see: Bellicum Pharmaceuticals (BLCM ) Investor Presentation - Slideshow

HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 23rd Annual Global Investment...

Gainers: ABVC BioPharma (NASDAQ:ABVC) +32%, Bellicum Pharmaceuticals (NASDAQ:BLCM) +22%, Evaxion Biotech (NASDAQ:EVAX) +22%, GBS (NASDAQ:GBS) +22%, PetVivo (NASDAQ:PETV) +17%. Losers: Avidity Biosciences (NASDAQ:RNA) -18%, So-Young (...